Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.
Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom.
复制标题
DOI：
10.1038/s41564-021-00947-3
复制
发表时间：
2021-09
影响因子：
28.3
通讯作者：
COVID-19 Infection Survey team
中科院分区：
文献类型：
--
作者：
Wei J;Stoesser N;Matthews PC;Ayoubkhani D;Studley R;Bell I;Bell JI;Newton JN;Farrar J;Diamond I;Rourke E;Howarth A;Marsden BD;Hoosdally S;Jones EY;Stuart DI;Crook DW;Peto TEA;Pouwels KB;Eyre DW;Walker AS;COVID-19 Infection Survey team
我们报告说，在45，965名接受ChAdOx 1或BNT 162 b2 SARS-CoV-2疫苗的成年人中，在那些先前没有感染SARS-CoV-2的人中，单次剂量后的血清转换率和定量抗体水平在老年人中较低，特别是在那些年龄>60岁的人中。两剂疫苗在所有年龄段都取得了很高的反应。与单剂量的BNT 162 b2相比，单剂量的ChAdOx 1的抗体水平增加得更慢并且达到更低的水平，但是在老年个体中单剂量的BNT 162 b2之后减弱。在描述性潜在类别模型中，我们确定了四个应答者亚组，包括一个“低应答者”组，该组更常见于年龄>75岁的人，男性和长期健康状况的个体。鉴于我们的研究结果，我们建议优先为那些以前没有感染过的人接种疫苗，并优先为年龄>60岁的人接种第二剂疫苗。需要进一步的数据来更好地理解定量抗体应答与疫苗介导的保护相关的程度。在来自英国的45，965名成年人中对ChAdOx 1和BNT 162 b2 COVID-19疫苗的抗体反应的纵向追踪为疫苗优先级提供了指示。
We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2, seroconversion rates and quantitative antibody levels after a single dose were lower in older individuals, especially in those aged >60 years. Two vaccine doses achieved high responses across all ages. Antibody levels increased more slowly and to lower levels with a single dose of ChAdOx1 compared with a single dose of BNT162b2, but waned following a single dose of BNT162b2 in older individuals. In descriptive latent class models, we identified four responder subgroups, including a ‘low responder’ group that more commonly consisted of people aged >75 years, males and individuals with long-term health conditions. Given our findings, we propose that available vaccines should be prioritized for those not previously infected and that second doses should be prioritized for individuals aged >60 years. Further data are needed to better understand the extent to which quantitative antibody responses are associated with vaccine-mediated protection. Longitudinal tracing of antibody responses to the ChAdOx1 and the BNT162b2 COVID-19 vaccines in 45,965 adults from the United Kingdom give indications for vaccine prioritization.
登录
查看更多内容
DOI：
10.1016/s0140-6736(20)32661-1
发表时间：
2021-01-09
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
DOI：
10.1111/tme.12746
发表时间：
2021-06
期刊：
Transfusion medicine (Oxford, England)
影响因子：
--
作者：
Harvala H;Robb ML;Watkins N;Ijaz S;Dicks S;Patel M;Supasa P;Wanwisa D;Liu C;Mongkolsapaya J;Bown A;Bailey D;Vipond R;Grayson N;Temperton N;Gupta S;Ploeg RJ;Bolton J;Fyfe A;Gopal R;Simmonds P;Screaton G;Thompson C;Brooks T;Zambon M;Miflin G;Roberts DJ
通讯作者：
Roberts DJ
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
DOI：
10.1016/s1473-3099(20)30634-4
发表时间：
2020-12
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
National SARS-CoV-2 Serology Assay Evaluation Group
通讯作者：
National SARS-CoV-2 Serology Assay Evaluation Group